Race and ethnicity in cancer therapy: What have we learned?

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 4, 2014, Pages 403-412

  Grenade, C ^a,b   Phelps, M A ^a   Villalona Calero, M A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TAMOXIFEN; TEGAFUR;

BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; COMORBIDITY; DIARRHEA; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; ETHNICITY; GENE MUTATION; GENETICS; GENOMICS; HUMAN; INFECTION; LIFESTYLE; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEUROPATHY; NEUTROPENIA; PATHOGENESIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; STOMACH CANCER; UTERINE CERVIX CANCER;

CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; INDIVIDUALIZED MEDICINE; LIFE STYLE; MALE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84897025767     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.5     Document Type: Review

References (86)

1. American Cancer Society Cancer Facts & Figures 2013. (American Cancer Society, Atlanta, GA, 2013.
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA. Cancer J. Clin. 63, 11-30 (2013.
3. Howlader, N et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute (2013). http://seer.cancer.gov/csr/1975-2010/.
4. Finkenauer, R., Pomerleau, C.S., Snedecor, S.M. & Pomerleau, O.F. Race differences in factors relating to smoking initiation. Addict. Behav. 34, 1056-1059 (2009.
5. Mustonen, T.K., Spencer, S.M., Hoskinson, R.A., Sachs, D.P. & Garvey, A.J. The influence of gender, race, and menthol content on tobacco exposure measures. Nicotine Tob. Res. 7, 581-590 (2005.
6. Gandhi, K.K., Foulds, J., Steinberg, M.B., Lu, S.E. & Williams, J.M. Lower quit rates among African American and Latino menthol cigarette smokers at a tobacco treatment clinic. Int. J. Clin. Pract. 63, 360-367 (2009.
7. Gardiner, P.S. The African Americanization of menthol cigarette use in the United States. Nicotine Tob. Res. 6 (suppl. 1), S55-S65 (2004.
8. Ahijevych, K. & Parsley, L.A. Smoke constituent exposure and stage of change in black and white women cigarette smokers. Addict. Behav. 24, 115-120 (1999.
9. Jones, M.R., Apelberg, B.J., Tellez-Plaza, M., Samet, J.M. & Navas-Acien, A. Menthol cigarettes, race/ethnicity, and biomarkers of tobacco use in U.S. adults: The 1999-2010 National Health and Nutrition Examination Survey (NHANES). Cancer Epidemiol. Biomarkers Prev. 22, 224-232 (2013.
10. Cykert, Set al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 303, 2368-2376 (2010.
11. Bach, P.B., Cramer, L.D., Warren, J.L. & Begg, C.B. Racial differences in the treatment of early-stage lung cancer. N. Engl. J. Med. 341, 1198-1205 (1999.
12. Hardy, D et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer 115, 2199-2211 (2009.
13. Lathan, C.S., Neville, B.A. & Earle, C.C. The effect of race on invasive staging and surgery in non-small-cell lung cancer-. J. Clin. Oncol. 24, 413-418 (2006.
14. Gordon, H.S., Street, R.L Jr, Sharf, B.F. & Souchek, J. Racial differences in doctors' information-giving and patients' participation. Cancer 107, 1313-1320 (2006.
15. Gadgeel, S.M., Severson, R.K., Kau, Y., Graff, J., Weiss, L.K & Kalemkerian, G.P. Impact of race in lung cancer: Analysis of temporal trends from a surveillance, epidemiology, and end results database. Chest 120, 55-63 (2001.
16. Blackstock, A.W. et al. Outcomes among African-American/non-African- American patients with advanced non-small-cell lung carcinoma: Report from the Cancer and Leukemia Group B. J. Natl. Cancer Inst. 94, 284-290 (2002.
17. van Ravesteyn, N.T. et al. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol. Biomarkers Prev. 20, 112-122 (2011.
18. Curtis, E., Quale, C., Haggstrom, D. & Smith-Bindman, R. Racial and ethnic differences in breast cancer survival: How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112, 171-180 (2008.
19. Chlebowski, R.T. et al. Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J. Natl. Cancer Inst. 97, 439-448 (2005.
20. Li, C.I., Malone, K.E. & Daling, J.R. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol. Biomarkers Prev. 11, 601-607 (2002.
21. Mclntyre-Seltman, K., Castle, P.E., Guido, R., Schiffman, M & Wheeler, C.M. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev 14, 1165-1170 (2005.
22. Dunn, B.K., Agurs-Collins, T., Browne, D., Lubet, R. & Johnson, K.A. Health disparities in breast cancer: Biology meets socioeconomic status. Breast Cancer Res. Treat. 121, 281-292 (2010.
23. Watlington, A.T., Byers, T., Mouchawar, J., Sauaia, A & Ellis, J. Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer? Cancer 109, 2093-2099 (2007.
24. Carey, L.A et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502 (2006.
25. Ihemelandu, C.U. et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J. Surg. Res. 143, 109-118 (2007.
26. Liu, J et al. Dietary patterns, abdominal visceral adipose tissue, and cardiometabolic risk factors in African Americans: The Jackson heart study. Obesity (Silver Spring). 21, 644-651 (2013.
27. Joshi, A.D., John, E.M., Koo, J., Ingles, S.A & Stern, M.C. Fish intake, cooking practices, and risk of prostate cancer: Results from a multi-ethnic case-control study. Cancer Causes Control 23, 405-420 (2012.
28. Sridhar, G., Masho, S.W., Adera, T., Ramakrishnan, V. & Roberts, J.D. Do African American men have lower survival from prostate cancer compared with White meñ A meta-Analysis. Am. J. Mens. Health 4, 189-206 (2010.
29. Cullen, Jrfsti et al. Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort. Prostate Cancer 2011, 234519 (2011.
30. Fisher, D.A., Jeffreys, A., Coffman, C.J. & Fasanella, K. Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol. Biomarkers Prev. 15, 1232-1235 (2006.
31. Doubeni, C.A et al. Racial differences in tumor stage and survival for colorectal cancer in an insured population. Cancer 109, 612-620 (2007.
32. Marcella, S. & Miller, J.E. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J. Clin. Epidemiol. 54, 359-366 (2001.
33. Chien, C., Morimoto, L.M., Tom, J & Li, C.I. Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer 104, 629-639 (2005.
34. Lieberman, D.A., Holub, J.L., Moravec, M.D., Eisen, G.M., Peters, D & Morris, C.D. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA 300, 1417-1422 (2008.
35. Shavers, V.L. Racial/ethnic variation in the anatomic subsite location of in situ and invasive cancers of the colon. J. Natl. Med. Assoc. 99, 733-748 (2007.
36. Al-Refaie, W.B. et al. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer 113, 461-469 (2008.
37. Kim, J. et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann. Oncol. 21, 152-160 (2010.
38. de Martel, C et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 13, 607-615 (2012.
39. Tsai, C.J., Perry, S., Sanchez, L. & Parsonnet, J. Helicobacter pylori infection in different generations of Hispanics in the San Francisco Bay Area. Am. J. Epidemiol. 162, 351-357 (2005.
40. Ferrante, J., Gonzalez, E., Roetzheim, R., Pal, N. & Woodard, L. Clinical and demographic predictors of late-stage cervical cancer Arch Fam Med. 9, 439-445 (2000.
41. Bensink, M.E et al. Costs and outcomes evaluation of patient navigation after abnormal cancer screening: Evidence from the Patient Navigation Research Program. Cancer. 120, 570-578 (2014.
42. Laz, T.H., Rahman, M & Berenson, A.B. Human papillomavirus vaccine uptake among 18-To 26-year-old women in the United States. Cancer. 119, 1386-1392 (2013.
43. McKinnon, R.A., Ward, M.B. & Sorich, M.J. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. 3, 751-759 (2007.
44. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011.
45. Huang, R.S & Gamazon, E.R. Translating pharmacogenomics discoveries into the clinic: An implementation framework. Genome Med. 5, 94 (2013.
46. Wilson, J.F et al. Population genetic structure of variable drug response. Nat Genet 29: 265-269 (2001.
47. Sekine, I et al. Common arm analysis: One approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 53, 157-164 (2006.
48. Sekine, I., Yamamoto, N., Nishio, K. & Saijo, N. Emerging ethnic differences in lung cancer therapy. Br. J. Cancer 99, 1757-1762 (2008.
49. Goh, B.C et al. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. Acta Oncol. 39, 225-229 (2000.
50. Goh, B.C. et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20, 3683-3690 (2002.
51. Millward, M.J. et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in Caucasian and Asian patients. Ann. Oncol. 14, 449-454 (2003.
52. Yamamoto, N., Tamura, T., Kamiya, Y., Sekine, I., Kunitoh, H. & Saijo, N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J. Clin. Oncol. 18, 2301-2308 (2000.
53. Kiyotani, K., Mushiroda, T., Kubo, M., Zembutsu, H., Sugiyama, Y & Nakamura, Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 99, 967-972 (2008.
54. Tran, A. et al. Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms. Clin. Pharmacol. Ther. 79, 570-580 (2006.
55. Walker, A.H. et al. Characterization of an allelic variant in the nifedipinespecific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum. Mutat. 12, 289 (1998.
56. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001.
57. Lewis, L.D. et al.; Cancer and Leukemia Group B. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin. Cancer Res. 13, 3302-3311 (2007.
58. Harris, J.W., Rahman, A., Kim, B.R., Guengerich, F.P & Collins, J.M. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994.
59. Rahman, A., Korzekwa, K.R., Grogan, J., Gonzalez, F.J & Harris, J.W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546 (1994.
60. Wandel, C., Kim, R.B. & Stein, C.M. Inactive excipients such as Cremophor can affect in vivo drug disposition. Clin. Pharmacol. Ther. 73, 394-396 (2003.
61. Nakajima, M. et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab. Dispos. 31, 687-690 (2003.
62. Henningsson, A. et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11, 8097-8104 (2005.
63. Iyer, L et al. UGT1A1 28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002.
64. Innocenti, F. et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004.
65. Hoskins, J.M., Goldberg, R.M., Qu, P., Ibrahim, J.G. & McLeod, H.L. UGT1A1 28 genotype and irinotecan-induced neutropenia: Dose matters. J. Natl. Cancer Inst. 99, 1290-1295 (2007.
66. Han, J.Y. et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 (2006.
67. Minami, H. et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1 6 and 28. Pharmacogenet. Genomics 17, 497-504 (2007.
68. Fujita, K. & Sasaki, Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr. Drug Metab. 8, 554-562 (2007.
69. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007.
70. Kiyotani, K et al. Impact of CYP2D6 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99, 995-999 (2008.
71. Ioannidis, J.P. Why most published research findings are false. PLoS Med. 2, e124 (2005.
72. Regan, M.M. et al.; Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial. J. Natl. Cancer Inst. 104, 441-451 (2012.
73. Rae, J.M. et al.; ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-Treated breast cancer patients. J. Natl. Cancer Inst. 104, 452-460 (2012.
74. Lum, D.W., Perel, P., Hingorani, A.D. & Holmes, M.V. CYP2D6 genotype and tamoxifen response for breast cancer: A systematic review and meta-Analysis. PLoS ONE 8, e76648 (2013.
75. Elens, L. et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21, 861-866 (2011.
76. Elens, L. et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57, 1574-1583 (2011.
77. Elens, L et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12, 1383-1396 (2011.
78. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11, 274-286 (2011.
79. He, P., Court, M.H., Greenblatt, D.J. & Von Moltke, L.L. Genotypephenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther. 77, 373-387 (2005.
80. National Center for Biotechnology Information. dbSNP Short Genetic Variations (2012). http://www.ncbi.nlm.nih.gov/snp.
81. Rotunno, M et al. Phase I metabolic genes and risk of lung cancer: Multiple polymorphisms and mRNA expression. PLoS ONE 4, e5652 (2009.
82. Wright, C.M. et al. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur. Respir. J. 35, 152-159 (2010.
83. Fukuoka, M. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29, 2866-2874 (2011.
84. Paez, J.G et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004.
85. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004.
86. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004.